Literature DB >> 12363203

Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: possible formation of an ETA-ETB receptor heterodimer.

Noboru Harada1, Akihiko Himeno, Kazuto Shigematsu, Kohji Sumikawa, Masami Niwa.   

Abstract

1. Interaction in the recognition of endothelin-1 (ET-1), a typical bivalent ET receptor-ligand, between ETA and ETB receptors was investigated in the rat anterior pituitary gland, using our quantitative receptor autoradiographic method with tissue sections preserving the cell-membrane structure and ET receptor-related compounds. 2. In saturation binding studies with increasing concentrations (0.77-200 pM) of 125I-ET-1 (nonselective bivalent radioligand), 125I-ET-1 binding to the rat anterior pituitary gland was saturable and single with a KD of 71 pM and a Bmax of 120 fmol mg(-1). When 1.0 microM BQ-123 (ETA antagonist) was added to the incubation buffer, binding parameters were 8.3 pM of KD and 8.0 fmol mg(-1) of Bmax, whereas 10 nM sarafotoxin S6c (ETB agonist) exerted little change in these binding parameters (KD, 72 pM; Bmax, 110 fmol mg(-1)). 3. Competition binding studies with a fixed amount (3.8 pM) of 125 I-ET-1 revealed that when 1.0 microM BQ-123 was present in the incubation buffer, ETB receptor-related compounds such as sarafotoxin S6c, ET-3, IRL1620 (ETB agonist), and BQ-788 (ETB antagonist) competitively inhibited 125I-ET-1 binding with K(i)s of 140,18,350 pM, and 14 nM, respectively, however, these compounds were not significant competitors for 125I-ET-1 binding in the case of absence of BQ-123. 4. In cold-ligand saturation studies with a fixed amount (390 pM) of 125I-IRL 1620 (ETB radioligand), IRL1620 bound to a single population of the ETB receptor, and no change was observed in binding characteristics in the presence of 1.0 microM BQ-123. 125I-IRL1620 binding was competitively inhibited by ET-1 and ET-3 in the absence of BQ-123, with K(i)s of 20 and 29 pM, respectively, the affinities being much the same as those of 29 nM, in the presence of 1.0 microM BQ-123. 5. Two nonbivalent ETA antagonists, BQ-123 and PD151242, were highly sensitive and full competitors for 125I-ET-1 binding (5.0 pM), in the presence of 10 nM sarafotoxin S6c. 6. Taken together with the present finding that mRNAs encoding the rat ETA and the ETB receptors are expressed in the anterior pituitary gland, we tentatively conclude that although there are ETA and ETB receptors with a functional binding capability for ET receptor-ligands, the ETB receptor does not independently recognize ET-1 without the aid of the ETA receptor. If this thesis is tenable, then ET-1 can bridge between the two receptors to form an ETA-ETB receptor heterodimer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12363203     DOI: 10.1023/a:1019822107048

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  37 in total

1.  Coexpression studies with endothelin receptor subtypes indicate the existence of intracellular cross-talk between ET(A) and ET(B) receptors.

Authors:  S Ozaki; K Ohwaki; M Ihara; K Ishikawa; M Yano
Journal:  J Biochem       Date:  1997-03       Impact factor: 3.387

Review 2.  Selective naltrexone-derived opioid receptor antagonists.

Authors:  A E Takemori; P S Portoghese
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

3.  The endothelin ETA receptor exists in the caudal solitary tract nucleus of the rat brain.

Authors:  S Shibata; M Niwa; A Himeno; N G Gana; K Shigematsu; M Matsumoto; K Yamashita; K Sumikawa; K Taniyama
Journal:  Cell Mol Neurobiol       Date:  1997-02       Impact factor: 5.046

4.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

5.  Characterization of 125I-endothelin-1 binding to rat and rabbit renal microvasculature.

Authors:  R M Edwards; W Trizna
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

6.  Characterization of endothelin receptors in the anterior pituitary gland.

Authors:  B Kanyicska; M E Freeman
Journal:  Am J Physiol       Date:  1993-10

7.  Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes.

Authors:  D L Williams; K L Jones; D J Pettibone; E V Lis; B V Clineschmidt
Journal:  Biochem Biophys Res Commun       Date:  1991-03-15       Impact factor: 3.575

8.  Endothelin ETA and ETB receptors facilitating parasympathetic neurotransmission in the rabbit trachea.

Authors:  T Yoneyama; M Hori; T Tanaka; Y Matsuda; H Karaki
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

9.  Heterogeneity of endothelin ETA receptor-mediated contractions in the rabbit saphenous vein.

Authors:  M Nishiyama; L H Shan; K Moroi; T Masaki; S Kimura
Journal:  Eur J Pharmacol       Date:  1995-11-14       Impact factor: 4.432

10.  A reversible radioligand specific for the ETB receptor: [125I]Tyr13-Suc-[Glu9,Ala11,15]-endothelin-1(8- 21), [125I]IRL 1620.

Authors:  T Watakabe; Y Urade; M Takai; I Umemura; T Okada
Journal:  Biochem Biophys Res Commun       Date:  1992-06-30       Impact factor: 3.575

View more
  23 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

2.  ET-1 induced Elevation of intracellular calcium in clonal neuronal and embryonic kidney cells involves endogenous endothelin-A receptors linked to phospholipase C through Gα(q/11).

Authors:  Jean-Pierre Montmayeur; Travis P Barr; Sarah A Kam; Samuel J Packer; Gary R Strichartz
Journal:  Pharmacol Res       Date:  2011-04-14       Impact factor: 7.658

3.  Short-term effects of endothelins on tyrosine hydroxylase activity and expression in the olfactory bulb of normotensive rats.

Authors:  Sabrina L Nabhen; Guadalupe Perfume; María A Battistone; Andrés Rossi; Tamara Abramoff; Liliana G Bianciotti; Marcelo S Vatta
Journal:  Neurochem Res       Date:  2008-10-11       Impact factor: 3.996

Review 4.  Endothelin receptors: what's new and what do we need to know?

Authors:  Stephanie W Watts
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-11       Impact factor: 3.619

Review 5.  Vascular plasticity in cerebrovascular disorders.

Authors:  Lars I H Edvinsson; Gro Klitgaard Povlsen
Journal:  J Cereb Blood Flow Metab       Date:  2011-05-11       Impact factor: 6.200

6.  Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults.

Authors:  Brian L Stauffer; Christian M Westby; Jared J Greiner; Gary P Van Guilder; Christopher A Desouza
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-25       Impact factor: 3.619

7.  Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  J Pain       Date:  2010-01-13       Impact factor: 5.820

8.  Differential endothelin receptor expression and function in rat myometrial cells and leiomyoma ELT3 cells.

Authors:  Marie-Noëlle Raymond; Philippe Robin; Federica De Zen; Ginette Vilain; Zahra Tanfin
Journal:  Endocrinology       Date:  2009-07-23       Impact factor: 4.736

9.  Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention.

Authors:  Yuqiang Ge; Alan Bagnall; Peter K Stricklett; David Webb; Yuri Kotelevtsev; Donald E Kohan
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-10

10.  Role of ERK/MAPK in endothelin receptor signaling in human aortic smooth muscle cells.

Authors:  Qing-wen Chen; Lars Edvinsson; Cang-Bao Xu
Journal:  BMC Cell Biol       Date:  2009-07-03       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.